New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTXLRN, GERN, ARGS, THLD, MDCO, EGRX, ANAC, SGMO, INSY, DSCOPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:20 EDTGERNGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
07:12 EDTINSYInsys Therapeutics price target raised to $57 from $53 at RBC Capital
Subscribe for More Information
December 11, 2014
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 10, 2014
13:54 EDTXLRNAcceleron management to meet with Leerink
Subscribe for More Information
December 9, 2014
12:22 EDTSGMOPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:12 EDTINSYInsys Therapeutics receives FDA orphan drug designation for LEP-ETU
Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.
December 8, 2014
16:24 EDTXLRNOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
14:06 EDTXLRNCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:35 EDTINSYInsys Therapeutics management to meet with Piper Jaffray
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:00 EDTINSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTINSYInsys Therapeutics initiated with a Buy at Jefferies
Subscribe for More Information
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information
07:29 EDTANACUBS to hold investor trip
Subscribe for More Information
07:11 EDTSGMOSangamo presents new data for Vivo Protein Replacement Platform
Sangamo announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform for the potentially curative treatment of such diseases. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. Data were also presented from Sangamo's partnered program with Shire that demonstrated that therapeutic levels of Factor IX, the human clotting factor that is deficient in hemophilia B, could be generated in a dose-dependent manner in non-human primates. There were no significant alterations in circulating albumin levels. Studies in mice also demonstrated stable Factor IX production from Sangamo's IVPRP for over 1 year.
December 7, 2014
16:48 EDTTHLDThreshold Pharmaceuticals announces data from TH-302 study
Threshold Pharmaceuticals announced new preliminary data from the Phase 2 component of an ongoing company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib, Velcade, and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. The median number of prior therapies was 8. The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses were observed in 2 of 7 evaluable patients overall and 2 of 4 evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California.
14:10 EDTXLRN, THLDAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTXLRNCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use